Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325671 | 0.85 | MMP2 (0.49) | LMNATRIM24HPGDKDM4EALDH1A1 | |
| SCHEMBL930646 | 0.85 | PKM (0.52) | LMNATP53TRIM24CTDSP1HPGD | |
| SCHEMBL5041575 | 0.83 | LMNA (0.48) | LMNATP53TRIM24CTDSP1HPGD | |
| SCHEMBL20326562 | 0.82 | CA1 (0.43) | CTDSP1ALDH1A1TSHRCA1CA2 | |
| SCHEMBL6954857 | 0.82 | TDP1 (0.56) | TP53MAPTTSHRCA1CA2 | |
| SCHEMBL6930567 | 0.82 | ALDH1A1 (0.42) | LMNATP53MAPTALDH1A1POLB | |
| SCHEMBL1028116 | 0.81 | CA1 (0.42) | LMNAALDH1A1TSHRHSD17B10CA1 | |
| SCHEMBL3737092 | 0.81 | CTDSP1 (0.47) | LMNATP53TRIM24CTDSP1HPGD | |
| SCHEMBL27669127 | 0.81 | CA1 (0.65) | ALDH1A1TSHRCA1CA2CA9 | |
| SCHEMBL123415 | 0.79 | MAPT (0.55) | LMNAHPGDMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611404-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220047575-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CHEMOCENTRYX, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738958-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020222717-A1 | AG-08 MOLECULE THAT IS A SAPOGENOL DERIVATIVE EXHIBITNG CYTOTOXIC EFFECTS BY ACTIVATING THE NECROSIS PATHWAY AND SYNTHESIS METHOD THEREOF | İZMİR YÜKSEK TEKNOLOJİ ENSTİTÜSÜ (TR) | 2020-11-05 | — | — | WO | disclosed |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CHEMOCENTRYX INC (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CHEMOCENTRYX INC (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3263564-B1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3263564-B1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES AS CCR(9) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10596163-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CHEMOCENTRYX, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-6858628-B2 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTOR & GAMBLE COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040138260-A1 | Substituted cyclic amine metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2004-07-15 | — | — | US | disclosed |
| US-20030191163-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20030105153-A1 | Substituted cyclic amine metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-06-05 | — | — | US | disclosed |
| US-6569855-B2 | Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity | THE PROCTER & GAMBLE COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0927161-B1 | SUBSTITUTED CYCLIC AMINE METALLOPROTEASE INHIBITORS | PROCTER & GAMBLE (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6417219-B1 | ENZYME INHIBITORS AND OSTEOARTHRITIS | THE PROCTOR & GAMBLE COMPANY | 2002-07-09 | — | — | US | disclosed |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-05-23 | — | — | US | disclosed |
| US-4874894-A | Process for the production of benzenesulfonamides | HILTON DAVIS CO. (US) | 1989-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | LMNA 1618/4885TP53 3193/4885TRIM24 3356/4885 |
| US-10596163-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR9, CCR1, CCR3 | LMNA 4475/4885TP53 3707/4885TRIM24 1695/4885 |
| US-12611404-B2 | Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides | CCR1, CCR9, CCR8 | LMNA 3792/4885TP53 4437/4885TRIM24 1826/4885 |
| US-20030191163-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | LMNA 1618/4885TP53 3193/4885TRIM24 3356/4885 |
| US-20040138260-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, MMP1, MMP25 | LMNA 2280/4885TP53 3422/4885TRIM24 2445/4885 |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | LMNA 1618/4885TP53 3193/4885TRIM24 3356/4885 |
| US-20030105153-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | LMNA 1618/4885TP53 3193/4885TRIM24 3356/4885 |
| US-20200197386-A1 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | CCR9, CCR1, CCR3 | LMNA 4321/4885TP53 3419/4885TRIM24 1611/4885 |
| US-20220047575-A1 | AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES | CCR9, CCR1, CCR3 | LMNA 4475/4885TP53 3707/4885TRIM24 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.